



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/178698/2020

European Medicines Agency decision P/0179/2020

of 15 May 2020

on the acceptance of a modification of an agreed paediatric investigation plan for setmelanotide (EMA-002209-PIP01-17-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



European Medicines Agency decision

P/0179/2020

of 15 May 2020

on the acceptance of a modification of an agreed paediatric investigation plan for setmelanotide (EMEA-002209-PIP01-17-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0164/2018 issued on 15 June 2018,

Having regard to the application submitted by Rhythm Pharmaceuticals, Inc on 20 December 2019 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 27 March 2020, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for setmelanotide, solution for injection, subcutaneous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Rhythm Pharmaceuticals, Inc, 222 Berkeley Street, 12th Floor, MA 02116 – Boston, United States.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/15043/2020
Amsterdam, 27 March 2020

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-002209-PIP01-17-M01

Scope of the application

Active substance(s):

Setmelanotide

Condition(s):

Treatment of appetite and general nutrition disorders

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Rhythm Pharmaceuticals, Inc

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Rhythm Pharmaceuticals, Inc submitted to the European Medicines Agency on 20 December 2019 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0164/2018 issued on 15 June 2018.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 28 January 2020.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.



Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of appetite and general nutrition disorders

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition

Treatment of appetite and general nutrition disorders

2.1.1. Indication(s) targeted by the PIP

Treatment of obesity and/or hyperphagia associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	2	Study 1 Development of a formulation which does not contain DSPE/mPEG and which has a dose interval longer than 1 day (ideally 1 week). Study 2 Development of a device capable of accurate and reproducible delivery of the lowest dosing volume required.

Non-clinical studies	2	<p>Study 3</p> <p>Evaluation of mPEG-DSPE in rat and monkey brain from chronic toxicity studies by immunohistochemistry. The objective is to determine localization of mPEG-DSPE in rat and monkey brain. (RM-493-TOX-023 and RM-493-TOX-024)</p> <p>Study 4</p> <p>Evaluation of the absorption, distribution, metabolism and elimination of mPEG-DSPE in rat using ¹⁴C-mPEG-DSPE (labelled on mPEG only).</p>
Clinical studies	3	<p>Study 5</p> <p>Open-label, 1-year study to evaluate the pharmacokinetics, safety and efficacy of setmelanotide in children from 2 to less than 18 years of age (and in adults) with Proopiomelanocortin (POMC) deficiency obesity. (Study RM-493-012)</p> <p>Study 6</p> <p>Open-label, uncontrolled, 3-months study, to evaluate the pharmacokinetics, safety and efficacy of setmelanotide in children from 2 to less than 18 years of age (and in adults) with rare genetic disorders of obesity. (RM-493-014)</p> <p>Study 7</p> <p>Open-label, 1-year study to evaluate the pharmacokinetics, safety and efficacy of setmelanotide in children from 2 to less than 18 years of age (and in adults) with leptin receptor (LEPR) deficiency obesity. (Study RM-493-015)</p>
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2024
Deferral for one or more measures contained in the paediatric investigation plan:	Yes